KCND3 Gene Spinocerebellar Ataxia Type 22 Autosomal Dominant Genetic Test sale cost 4400 AED
SMN1 Gene Spinal Muscular Atrophy Type 3 Genetic Test sale cost 4400 AED SMN1 Gene Spinal Muscular Atrophy Type 3 Genetic Test Cost 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
TDP1 Gene Spinocerebellar Ataxia with Axonal Neuropathy Autosomal Recessive Genetic Test sale cost 4400 AED TDP1 Gene Spinocerebellar Ataxia with Axonal Neuropathy Autosomal Recessive Genetic Test Cost 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
Sale!

KCND3 Gene Spinocerebellar Ataxia Type 22 Autosomal Dominant Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The KCND3 gene spinocerebellar ataxia type 22 autosomal dominant genetic test is a specialized diagnostic tool designed to identify mutations in the KCND3 gene, which are linked to the development of spinocerebellar ataxia type 22 (SCA22). SCA22 is a neurological condition characterized by progressive ataxia, which includes difficulties with coordination and balance due to cerebellar degeneration. As an autosomal dominant disorder, a mutation in just one of the two copies of the gene in each cell is sufficient to cause the condition, meaning it can be directly passed from an affected parent to their child.

The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in a laboratory setting to detect mutations in the KCND3 gene. This genetic testing is crucial for individuals with a family history of SCA22 or those exhibiting symptoms, as it can confirm a diagnosis, inform treatment decisions, and help with family planning.

Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the cost of the KCND3 gene spinocerebellar ataxia type 22 autosomal dominant genetic test is set at 4400 AED. This investment in testing is essential for those seeking clarity on their genetic status concerning SCA22, enabling them and their healthcare providers to make informed decisions regarding their health and future.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test

Are you or your loved ones experiencing problems with movement and coordination? It could be a result of Spinocerebellar Ataxia Type 22 (SCA22), a progressive genetic disorder affecting the cerebellum. To confirm a diagnosis and provide essential information for genetic counseling and family planning, DNA Labs UAE offers the KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test.

Test Details

The KCND3 gene is associated with SCA22, an autosomal dominant genetic disorder characterized by the degeneration of the cerebellum. Our Next-Generation Sequencing (NGS) Genetic Test utilizes advanced sequencing technology to analyze multiple genes simultaneously. By examining the KCND3 gene, this test can identify any mutations or variations that may be responsible for the development of SCA22.

Components and Price

The KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test is priced at 4400.0 AED. The test requires a blood sample, extracted DNA, or one drop of blood on an FTA Card.

Report Delivery and Method

After conducting the test, the report will be delivered within 3 to 4 weeks. Our NGS Technology ensures accurate and efficient analysis of the genetic material.

Test Type and Doctor

This test falls under the category of Neurological Disorders and is conducted by our experienced Neurologist. Our dedicated Test Department in Genetics ensures the highest level of accuracy and professionalism.

Pre Test Information

Before undergoing the KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test, it is essential to provide the clinical history of the patient. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected by SCA22. This information is crucial for accurate diagnosis and appropriate guidance.

Who Should Consider the Test?

This genetic test is recommended for individuals who exhibit symptoms of SCA22, as well as those who have a family history of the condition. Identifying mutations or variations in the KCND3 gene can help confirm a diagnosis, provide valuable information for genetic counseling, and aid in family planning.

Furthermore, this test can also be beneficial for identifying individuals who are at risk of developing SCA22 but have not yet shown symptoms. Early detection and intervention can significantly improve the management and treatment of the condition.

It is important to note that the KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test should only be performed by a qualified healthcare professional or genetic counselor. These experts can interpret the results accurately and provide appropriate guidance and support throughout the testing process.

Don’t let movement and coordination problems go undiagnosed. Contact DNA Labs UAE today to schedule your KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test and take control of your genetic health.

Test Name KCND3 Gene Spinocerebellar ataxia type 22 autosomal dominant Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for KCND3 Gene Spinocerebellar ataxia type 22, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with KCND3 Gene Spinocerebellar ataxia type 22, autosomal dominant
Test Details

The KCND3 gene is associated with a condition called Spinocerebellar Ataxia Type 22 (SCA22). SCA22 is an autosomal dominant genetic disorder characterized by progressive degeneration of the cerebellum, leading to problems with movement and coordination.

NGS (Next-Generation Sequencing) Genetic Test is a type of genetic testing that uses advanced sequencing technology to analyze multiple genes simultaneously. In the case of SCA22, an NGS genetic test can identify any mutations or variations in the KCND3 gene that may be responsible for the development of the condition.

This type of genetic test can help in confirming a diagnosis of SCA22 and also provide important information for genetic counseling and family planning. It can also be useful in identifying individuals who are at risk of developing the condition but have not yet shown symptoms.

It is important to note that genetic testing for SCA22 should be performed by a qualified healthcare professional or genetic counselor, who can interpret the results and provide appropriate guidance and support.

SKU: TEST-2066 Category:

Related products